Opdualag – a fixed-dose combination of LAG-3 inhibitor relatlimab and BMS' PD-1 inhibitor Opdivo (nivolumab) – was approved as a first-line therapy for unresectable or metastatic melanoma by ...

Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in melanoma, dashing its hopes of moving the drug earlier in the treatment pathway.

Bristol Myers Squibb’s (BMJ) Phase III Relativity-098 trial examining its stage III-IV melanoma treatment, Opdualag, has failed to meet its primary endpoint of recurrence-free survival (RFS ...